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Abstract Introduction
Chronic metabolic acidosis results in metabolic bone disease,
calcium nephrolithiasis, and growth retardation. The pathogen-
esis of each of these sequelae is poorly understood in humans.
Wetherefore investigated the effects of chronic extrarenal met-
abolic acidosis on the regulation of 1,25-(OH)2D, parathyroid
hormone, calcium, and phosphate metabolism in normal hu-
mans. Chronic extrarenal metabolic acidosis was induced by
administering two different doses of NH4CI 12.1 (low dose) and
4.2 (high dose) mmol/kg body wt per d, respectively] to four
male volunteers each during metabolic balance conditions.
Plasma IHCO3I decreased by 4.5±0.4 mmol/liter in the low
dose and by 9.1±0.3 mmol/liter (P < 0.001 ) in the high dose
group. Metabolic acidosis induced renal hypophosphatemia,
which strongly correlated with the severity of acidosis (Plasma
1P041 on plasma [HCO-1; r = 0.721, P < 0.001). Both meta-
bolic clearance and production rates of 1,25-(OH)2D increased
in both groups. In the high dose group, the percentage increase
in production rate was much greater than the percentage in-
crease in metabolic clearance rate, resulting in a significantly
increased serum 1,25-(OH)2D concentration. A strong inverse
correlation was observed for serum 1,25-(OH)2D concentra-
tion on both plasma IP041 (r = -0.711, P< 0.001 ) and plasma
IHCO31 (r = -0.725, P < 0.001). Plasma ionized calcium
concentration did not change in either group whereas intact
serum parathyroid hormone concentration decreased signifi-
cantly in the high dose group. In conclusion, metabolic acidosis
results in graded increases in serum 1,25-(OH)2D concentra-
tion by stimulating its production rate in humans. The in-
creased production rate is explained by acidosis-induced hypo-
phosphatemia/cellular phosphate depletion resulting at least
in part from decreased renal tubular phosphate reabsorption.
The decreased serum intact parathyroid hormone levels in
more severe acidosis may be the consequence of hypophospha-
temia and/or increased serum 1,25-(OH)2D concentrations.
(J. Clin. Invest. 1992. 90:2456-2463.) Key words: metabolic
acidosis. 1,25-(OH)2D- parathyroid hormone * metabolic
clearance rate * production rate * hypophosphatemia * NH4Cl
feeding
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Chronic metabolic acidosis occurs as the result of an increase in
the systemic acid load (by either extrarenal loss of base or in-
crease in acid production) or as the result of congenital or ac-
quired defects in renal acid excretion (e.g., renal tubular or
uremic acidosis). Metabolic acidosis profoundly affects cal-
cium and phosphate metabolism resulting in calcium losses
from bone ( 1 ) in association with hypercalciuria. Important
clinical sequelae are a metabolic bone disease resembling os-
teomalacia (2-8) and calcium nephrolithiasis (9).
Reduced serum concentrations of the active metabolite of
vitamin D, 1,25-(OH)2D, have been implicated in mediating
the acidosis-induced metabolic bone disease (8, 10, I 1). The
low 1,25- (OH )2D serum concentrations have been pathogenet-
ically attributed to diminished renal l-alpha-hydroxylase activ-
ity ( 12-14), although not all studies have been consistent with
an impaired conversion of 25-(OH)D to 1,25-(OH)2D ( 15).
However, the results of measurements of serum 1,25-
(OH)2D concentration during experimentally induced meta-
bolic acidosis have not been consistent: reported values have
ranged from increased to unchanged to decreased mean con-
centrations ( 15-19). These inconsistencies may have been due
in part to the experimental difficulties in controlling acidosis-
induced alterations in the plasma concentrations of known
modulators of 1,25-(OH)2D production: phosphate (20-22),
calcium (23), and parathyroid hormone (23, 24). Moreover,
small doses of NH4Cl were generally administered and there-
fore relatively mild degrees of acidemia and only minor reduc-
tions in plasma bicarbonate concentration were induced. An
additional difficulty in demonstrating consistent and signifi-
cant changes in serum 1,25-(OH)2D concentration may be
attributed to the reliance on unpaired observations rather than
repeated measurements in the same subjects.
Recent preliminary data from our group (25) indicated
that NH4Cl-induced metabolic acidosis of moderate severity
(plasma bicarbonate concentration - 12 mmol/liter) in-
creased steady state 1,25-(OH)2D serum concentration. We
therefore have investigated the chronic regulation of 1,25-
(OH)2D metabolism in chronic extrarenal metabolic acidosis
and administered NH4C1 in two widely different doses for 8 d
each in two groups of normal human subjects. The results indi-
cate that serum 1,25-(OH)2D concentration is increased
greatly by moderate to severe metabolic acidosis. The incre-
ment in serum concentration is due to an increase in produc-
tion rate (PR),' which at moderate to severe degrees of acidosis
becomes of sufficient magnitude to override an increase in the
1. Abbreviations used in this paper: FE, fractional excretion; MCR,
metabolic clearance rate; PR, production rate.
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metabolic clearance rate (MCR). Hypophosphatemia, in-
duced by renal phosphate losses, was found to be the stimulus
for augmented 1,25-(OH)2D production rate in human meta-
bolic acidosis.
Methods
The protocol was designed to measure the effects of chronic NH4Cl-in-
duced metabolic acidosis on calcium, phosphate, and 1,25-(OH)2D
metabolism as well as serum parathyroid hormone levels in normal
humans. These parameters were determined in eight normal male sub-
jects during metabolic balance studies. None were smokers or were
taking any drugs before and during the study. They ate a constant
metabolic diet for 2 5 d before the study (prefeeding phase) and during
the two study periods (control and acidosis). The diet provided the
following for every kilogram of body weight per day: 1.91 mmol so-
dium, 1.45 mmol potassium, 0.395 mmol (15.8 mg) of calcium, 0.51
mmol (15.8 mg) phosphorus, 15.7 mmol (0.22 g) nitrogen, 35 kcal,
and 43.1 ml of water.
Fasting arterialized venous blood samples (26) were obtained in a
heparin-coated syringe from a heated hand or forearm vein at 7 a.m.
Blood samples were accepted for acid-base analysis only if the partial
pressure of oxygen was > 70 mmHg(9.3 kPa). Blood samples for 1,25-
(OH)2D and parathyroid hormone were obtained in nonheparinized
syringes. Weight and oral temperatures were determined at the time of
blood sampling; 24-h urine samples were collected in plastic bottles
containing mineral oil and thymol-chloroform preservative. Exercise
was limited to minimal ambulation throughout the study. During both
study periods a subject was considered to be in a steady state when
plasma values obtained on three consecutive days varied by no more
than 1.5 mmol/liter for bicarbonate and by < 3 mmHg(0.4 kPa) for
PaCO2. To analyze the effect of metabolic acidosis on diurnal variation
of parathyroid hormone, 1,25-(OH)2D, calcium, and phosphate val-
ues, additional blood samples were drawn under nonfasting conditions
at approximately 6 p.m. during steady state days.
All subjects volunteered for the study, were paid for their participa-
tion, and gave informed consent. The study protocol was approved by
the ethics committee of the University of Berne School of Medicine.
Experimental design. To establish a normal baseline, the subjects
were studied initially for 4 d while ingesting the metabolic diet without
NH4C1(control period). After the control period two different degrees
of metabolic acidosis were induced by NH4C1 administration. Four
male subjects (mean age [±SD] 30±6.4 y; body weight 60.7±2.4 kg)
were fed 2.1 mmol NH4Cl/kg in gelatin capsules in six divided doses.
Four additional male subjects (mean age [±SD] 27.3±7.3 y; body
weight 64.4±4.6 kg) were fed 4.2 mmol NH4CI/kg daily also in six
divided doses. Observations were carried out for 8 d, during which
period a new steady state of acid-base equilibrium was established in
all subjects.
Analytical procedures. All measurements were performed in dupli-
cate. Analysis of plasma and urine electrolyte and acid-base composi-
tion were performed as described previously (27). Plasma ionized cal-
cium was measured with an ion-selective electrode at the prevailing
blood pH under anaerobic conditions (intraassay coefficient of varia-
tion = 0.9%, interassay coefficient of variation = 1.1%, model 634,
Ciba Corning, Medfield, MA). Serum intact parathyroid hormone
(28) and 1,25-(OH)2D (29) levels were measured with specific radio-
immunoassay and radioreceptor kits, respectively (Nichols Institute,
San Juan Capistrano, CA). MCRand PR of 1,25-(OH)2D were esti-
mated by the primed-infusion technique of Eastell et al. (30). 1,25-
[3H-26,27](OH)2D3 (159 Ci/mmol) was obtained from Amersham
Corp. (Arlington Heights, IL). A loading dose of 624±34 dpm/kg was
infused over 2 min and the cannula flushed with 2 ml of 0.9% sterile
saline. One tenth of this loading dose was then infused per hour over a
period of 6 h (infusion rate [dpm/kg per h]:loading dose [dpm/kg]
= 1:10). Radioactivity was determined in 1 ml of plasma. A constant
level of plasma radioactivity (linear regression slope of plasma concen-
tration of 3H-1,25(OH)2D3 vs. time not significantly different from
zero) was reached between 150 and 210 min. Plasma samples from
blood drawn every 15 min between 300 and 360 min after administra-
tion of the loading dose were used for analysis. The MCRof endoge-
nous 1,25-(OH)2D is assumed to be equal to that of intravenously
administered [3H]-l1,25(OH)2D3. At steady state, MCRwas calcu-
lated according to the relationship (31) MCR(ml/min) = (rate of
infusion of [3H ] -1,25 (OH)2D3 [dpm/min] )/(plasma concentration
of [3H]-1,25(OH)2D3 [dpm/ml]). The value for plasma concentra-
tion of [3H]-1,25(OH)2D3 is the mean of five separate determinations
of [3H]-1,25(OH)2D2 obtained at steady state. The intraassay coeffi-
cient of variation of [3H]-1,25(OH)2D was 6.2%, the interassay coeffi-
cient of variation was 7.3% (tritium concentration 310 dpm/min).
The PRof 1,25-(OH)2D was calculated according to the relationship
PR (,gg/d) = MCR(ml/min) X serum concentration of endogenous
1,25-(OH)2D (ug/ml) X 1440 min/d.
Results are reported as mean±SEMunless stated otherwise. Statis-
tical significance was determined by simple and multiple linear regres-
sion, covariance analysis, and Student's t test for paired or unpaired
data, as appropriate.
Results
Both groups of subjects tolerated the protocol well. The mean
steady state plasma acid-base and electrolyte composition, al-
bumin concentration, alkaline phosphatase activity, creatinine
clearance rate, and body weight are shown in Table I. The
steady state values for urinary acid-base and electrolyte excre-
tion are given in Table II. The administration of NH4Cl de-
creased the mean±SEMsteady state plasma bicarbonate con-
centration by 4.5±0.3 mmol/liter in the group receiving 2.1
mmol (low dose group) and by 9.1±0.4 mmol/liter in the
group receiving 4.2 mmol NH4Cl/kg body wt per d (high dose
group, P < 0.001 ). A similar dose-response to the two levels of
oral acid load was observed in the rate of net acid excretion
(NAE, Table II): NAEincreased to 142.5±7.4 mmol/24 h in
the low dose group, whereas subjects in the high dose group
(ingesting twice the amount of NH4Cl as the low dose group)
excreted approximately twofold more acid (270.2±9.6 mmol/
24 h, P< 0.001 ). All subjects in both groups lost weight signifi-
cantly. NH4C1 feeding decreased plasma potassium concentra-
tion and albumin concentration significantly only in the high
dose group.
The effects of metabolic acidosis on calcium, phosphate,
1,25-(OH)2D metabolism, and parathyroid hormone are illus-
trated in Table III and Figs. 1 and 2, which depict the mean
daily values for the low and high dose groups. Steady state
plasma-ionized calcium concentration did not change signifi-
cantly in response to metabolic acidosis in either group, despite
a large and significant increase in the total and fractional uri-
nary excretions of calcium. However, as illustrated in Fig. 2,
there was a transient small increase in calcium concentration
during the adaptation to metabolic acidosis. This transient in-
crease was observed only in the high dose group. Plasma phos-
phate concentration decreased in a dose-dependent fashion in
response to metabolic acidosis: whereas hypophosphatemia
was mild and not statistically significant in the low dose group,
the decrement in plasma phosphate concentration of
-0.26±0.05 mmol/liter in the high dose group was significant
(P < 0.001 ). Acidosis-induced hypophosphatemia in the high
dose group averaged 0.87±0.04 mmol/liter and was signifi-
cantly more severe than that observed in the low dose group
Metabolic Acidosis Increases Serum 1,25-(OH)2D Concentration 2457
Table 1. Effect of Chronic NH4Cl Administration on Fasting Plasma Acid-Base and Electrolyte Composition*
Unmeasured Alkaline Creatinine
H+ PaaCO2 HCO anions Na+ K+ C1 Albumin phosphate clearance Weight
nmoi/liter mmHg mmol/liter g/liter mi/s kg
Low dose group
(2.1 mmol NH4
Cl/kg body wt per
day, n = 4)
Control 37.8±0.6 40.3±0.8 25.3±0.3 16.8±0.6 142.0±1.0 3.9±0.05 103.8±0.6 42.5±0.6 64±3 2.00±0.08 60.7±1.2
Metabolic acidosis,
Days 6-8 41.8±0.4t 36.6±0.5* 20.8±0.4$ 14.7±0.9§ 139.4±0.6 3.9±0.06 107.6±0.5* 41.7±0.5 66±3 2.05±0.05 59.0±1.2*
High dose group
(4.2 mmol NH4
Cl/kg body wt per
day, n = 4)
Control 37.9±0.9 40.1±0.5 25.5±0.4 17.6±0.6 142.3±0.9 4.0±0.04 103.7±0.7 43.8±0.5 78±3 2.11±0.07 64.4±2.3
Metabolic acidosis,
Days 6-8 48.2±0.8$ 33.0±0.7$ 16.4±0.4* 15.3±0.7$ 139.0±0.7 3.7±0.07" 111.2±0.4$ 42.3±0.6§ 84±3 2.24±0.08 62.5±2.3$
* Means±SEM. H+ denotes hydrogen ion, PaCO2arterial carbon dioxide tension, HCO- bicarbonate, Na' sodium, K+ potassium, and Cl chloride. To convert values
for PaCO2 to kP, multiply by 0.1333. Unmeasured anions were calculated as (Na+ + K+) - (Cl- + HCOj)mmol/ileri
* P < 0.001 ; I P < 0.01; 11 P < 0.05 for the comparison to the control period within the same study group.
(1.00±0.02 mmol/liter, P< 0.005). The fact that urinary phos-
phate excretion was enhanced in the steady state despite a
lower filtered load of phosphate (Table III, Figs. 1 and 2) indi-
cates that metabolic acidosis-induced hypophosphatemia is at
least in part of renal origin.
Low dose NH4Cl resulted in a small, but nonsignificant
increase in serum 1,25-(OH)2D and a small, but nonsignifi-
cant decrease in intact parathyroid hormone concentration. In
the high dose group, serum 1,25-(OH)2D increased signifi-
cantly by 15.8±2.9 pg/ml (P < 0.001) and parathyroid hor-
mone decreased significantly by 4.9±1.8 pg/ml (P < 0.025,
Table III, Figs. 1 and 2). Metabolic acidosis increased the
MCRof 1,25-(OH)2D significantly and to a similar degree in
both groups. The PRof 1,25-(OH)2D increased by 0.61±0.25
Alg/24 h (P < 0.025) in the low dose groups and by 1.14±0.4
tig/24 h in the high dose group (P < 0.005, Table III). Thus,
the percentage stimulation of PR for high dose NH4Cl was
greater than the percentage increase in MCR, resulting in in-
creased steady state serum 1,25-(OH)2D concentrations in re-
sponse to metabolic acidosis.
The relationship between steady state plasma phosphate
and plasma bicarbonate concentrations are shown in Fig. 3 A,
and the relationships between each of these parameters and
serum 1,25-(OH)2D concentration are depicted in Fig. 3 Band
Table II. Effect of Chronic NH4CI Administration on Urinary Acid-Base and Electrolyte Excretion*
Titratable Net




body wt per day;
n = 4)
Control 6.30±0.07 19.5±2.2 15.3±1.5 4.5±1.4 30.3±2.8 141.3±8.7 86.8±3.2 144.9±7.3
Metabolic acidosis
Day 1 4.99±0.11* 116.4±4.3* 22.2±1.5"1 1.1±0.5* 137.2±6.8* 156.1±4.2* 112.5±5.8" 321.6±15.3*
Days 6-8 4.96±0.03* 119.4±5.2* 23.6±0.4" 0.5±0.6* 142.5±7.3* 133.8±7.1 89.9±3.3 255.3±12.3*
High dose group
(4.2 mmol NH4CI/kg
body wt per day;
n = 4)
Control 6.22±0.13 20.7±1.2 16.2±1.4 5.1±1.2 31.8±3.1 145.5±8.4 91.4±3.2 150.5±8.1
Metabolic acidosis
Day 1 4.76±0.03* 175.0±5.1* 31.3±1.6* 0.5±1.1* 205.9±8.9* 256.2±6.4* 142.3±4.7§ 428.1±11.9$
Days 6-8 5.02±0.03* 232.1±9.3t 38.5±1.6* 0.4±1.0* 270.2±9.6* 141.5±6.7 109.0±5.1 426.1±13.5*
* Mean±SEM. NH4denotes ammonia/ammonium.
* P < 0.00 1; § P < 0.025; and 11 P < 0.05 for comparison with control steady state period (last 3 d of control period).
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Table III. Mineral and Endocrine Data*
Group and Intact 1,25(OH)2 MCR1.25(OH)2 PR 1,25(OH)2
study period Ca+ PO4P PTH vit D Cau P04U FEcA FEP04 vit D vit D
mmoi/liter pg/mi mmol/24 h % mllmin ug/24 h
Low dose group
(NH4 Cl 2.1 mmol/kg
body wt, n = 4)
Control 1.33±0.01 1.06±0.04 21.4±6.3 32.3±3.1 6.08±0.62 26.0±1.9 1.74±0.24 16.8±1.2 32.5±2.6 1.35±0.1
Acidosis
Day 1 1.33±0.01 1.13±0.05 25.3±5.1 27.8±3.4 8.07±1.51 32.8±3.9 2.00±0.50 20.0±1.6
Days 6-8 1.30±0.01 1.00±0.02 23.3±4.5 34.3±3.1 9.82±1.084 30.2±1.5 2.76±0.48' 20.1±1.2§ 41.7±2.2V 1.96±0.3"
2;A (day 8) +21.0" +31.9*
High dose group
(NH4CI 4.2 mmol/kg
body wt; n = 4)
Control 1.30±0.02 1.13±0.04 29.5±6.3 25.0±3.4 8.31±0.38 28.6±0.8 2.11±0.11 15.4±0.9 33.7±3.0 1.33±0.1
Acidosis
Day 1 1.35±0.01 1.12±0.08 29.0±4.8 31.5±2.9 12.66±0.55 36.8±2.4" 3.41±0.31" 22.9±1.6'
Days 6-8 1.32±0.01 0.87±0.04$ 20.9±3.2" 40.3±3.5* 19.20±0.41 35.2±2.2" 4.79±0.18* 23.5±1.3§ 42.3±3.2' 2.47±0.4'
2; (day 8) +67.8t*$ +91.3*$$
* Means±SEM. IA denotes the cumulative change in excretion, calculated as the accumulated sum of the daily differences from the previous
steady state period. Ca2+ denotes ionized calcium, P042- phosphate, and suffixes P and U plasma and urine, respectively.
P < 0.001; § P < 0.005; "l P < 0.025; ' P < 0.05 for the comparison to the control period within the same study period; ** P < 0.005;
** P < 0.05 for the comparison between high and low dose group; §§ significantly different from zero (P < 0.005).
C, respectively. Plasma phosphate concentration correlated
positively and significantly with plasma bicarbonate concen-
tration (r = 0.72, P < 0.001). A strong, negative correlation
was observed between serum 1,25-(OH)2D concentration and
plasma phosphate concentration (r = -0.71 1, P < 0.001) as
well as plasma bicarbonate concentration (r = -0.725, P
< 0.001). Multiple regression analysis of the relationship of
1,25-(OH)2D on plasma phosphate and bicarbonate concen-
trations revealed only slightly better correlation (r = 0.756, P
< 0.001 ). Further partial correlation analysis of the relation-
ship of serum 1,25-(OH)2D concentration on a combination
of parameters yielded the following partial correlation coeffi-
cients: (a) 1,25-(OH)2D on plasma phosphate at constant
plasma ionized calcium concentration (r = -0.705, P< 0.001),
(b) 1,25-(OH)2D on plasma phosphate at constant serum in-
tact parathyroid hormone concentration (r = -0.668, P
< 0.001), (c) 1,25-(OH)2D on plasma ionized calcium at con-
stant phosphate concentration (r = -0.310, P > 0.05).
Dietary potassium loading has been reported recently to
produce renal hyperphosphatemia and a decrease in serum
1,25-(OH)2D concentration in humans (32). Thus, the possi-
bility might be considered that renal potassium wasting in-
duced by chronic mineral acidosis could induce both hypo-
phosphatemia and secondarily increased serum 1,25-(OH)2D
concentration. However, no significant correlation was ob-
tained for the relation of steady state plasma phosphate on
plasma potassium concentration (r = 0.475), although a signifi-
cant inverse correlation does obtain for serum 1,25-(OH)2D
on plasma potassium concentration (r = 0.542, P< 0.05). This
correlation is, however, substantially weaker than that for
serum 1 ,25-(OH)2D on plasma phosphate concentration (Fig.
3B).
To evaluate a possible influence of metabolic acidosis on
the diurnal variation of plasma ionized calcium, plasma phos-
phate, serum 1,25-(OH)2D, and serum intact parathyroid hor-
mone concentrations, these values were determined at 1800 as
well as at 0700 during steady state days during both the control
and experimental periods. As illustrated in Fig. 4, metabolic
acidosis did not affect the evening values of any of these param-
eters, suggesting that diurnal variation was not changed signifi-
cantly. However, a more detailed analysis of the diurnal pat-
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Figure 1. Effect of low dose NH4C1 feeding (2.1 mmol/kg body wt per
day) on the plasma bicarbonate (HCO ), ionized calcium (Ca"+),
and phosphate (PO4) concentrations, the fractional excretions of cal-
cium (FEc.) and phosphate (FEpO4), and serum intact parathyroid
hormone (PTH) and 1,25-(OH)2D concentrations. Values are
mean±SEM.
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Figure 2. Effect of high dose NH4C1 feeding (4.2 mmol/kg body wt
per day) on the plasma bicarbonate (HCO ), ionized calcium
(Ca"+), and phosphate (P04) concentrations, the fractional excre-
tions of calcium (FEc..) and phosphate (FEp4), and serum intact
parathyroid hormone (PTH) and 1,25-(OH)2D concentrations. Val-
ues are mean±SEM.
tern of these parameters in response to metabolic acidosis was
not performed nor was it a goal of these studies.
Discussion
Chronic metabolic acidosis is associated with clinically impor-
tant osteomalacic and osteopenic bone disease, growth retarda-
tion, and calcium nephrolithiasis. To gain more insight into the
mechanisms of these clinical syndromes, the present studies
were designed to examine the regulation of 1,25-(OH)2D me-
tabolism, parathyroid hormone, and calcium and phosphate
balance in metabolic acidosis. The novel findings are (a) meta-
bolic acidosis significantly increases both the MCRand the PR
of 1,25-(OH)2D; (b) at the lower plasma bicarbonate concen-
trations of more severe acidosis the increase in PRoverrides the
increase in MCR(Table III); thus, (c) resulting in a highly
significant increase in serum 1,25-(OH)2D concentration in
metabolic acidosis of moderate severity (plasma [HCO -] rang-
ing from 13 to 18 mmol/liter, high NH4C1dose group) and a
smaller but nonsignificant increase in less severe degrees of
acidosis (plasma [HCO- ] ranging from 17 to 22 mmol/liter,
low NH4C1dose group, Table III, Figs. 1 and 2); (d) metabolic
acidosis induced hypophosphatemia of renal origin (Table III,
Figs. 1 and 2) with a strong direct correlation of plasma phos-
phate with plasma bicarbonate concentration (Fig. 3 A) and an
equally strong inverse correlation of serum 1,25-(OH)2D con-
centration with plasma phosphate concentration (Fig. 3 B);
and (e) intact parathyroid hormone decreased significantly in
response to metabolic acidosis in the high dose group (Table
III, Fig. 2).
Our finding of an enhanced 1,25-(OH)2D MCRrepresents
the first report of this measurement in acidosis and is consistent
with recent results of studies demonstrating enhanced degrada-
tion of labeled 1,25-(OH)2D in vitamin D-deficient chicks
with NH4Cl-induced metabolic acidosis (33). The mechanism
of the apparent acidosis-induced enhancement of MCRhas
not been investigated in this study. However, it is interesting to
note that the MCRof another steroid hormone, aldosterone, is
enhanced in response to dietary potassium depletion (34). The
present observations indicate that the observed increase in the
MCRcan be overridden by an even greater increase in the PR
of 1,25-(OH)2D. Weare unaware of other metabolic distur-
bances that simultaneously increase both the PRand MCRof
any hormone.
Dietary-induced decreases and increases in plasma phos-
phate concentration have been shown to increase and decrease
serum 1,25-(OH)2D concentration, respectively, in humans by
altering its PR (20-22). Hypophosphatemia, hypocalcemia,
and parathyroid hormone excess are the best-known stimula-
tors of 1 ,25-(OH)2D PR. When all steady state values of this
study were analyzed (Fig. 3 B), a significant inverse correlation
was demonstrable for the relation of serum 1,25-(OH)2D as a
function of plasma phosphate concentration. This observation
coupled with the findings that plasma ionized calcium concen-
tration did not change and that parathyroid hormone serum
concentrations were unchanged (low dose group) or even de-
creased (high dose group) indicate a dominant role for hypo-
phosphatemia and/or cellular phosphate depletion in acidosis-
induced stimulation of 1,25-(OH)2D production.2
The present studies also demonstrate a strikingly strong di-
rect correlation of plasma phosphate with plasma bicarbonate
concentration (Fig. 3 A), consistent with our previous observa-
tions in another group of humans (25). However, other studies
in humans have not reported consistent acidosis-induced
changes in plasma phosphate concentration, which was found
to be either unchanged (35-37) or decreased (38, 39). Similar
inconsistencies are reported in previous animal studies (rat,
dog, and chick; references 12, 16-18, 33, 40-44). However, the
results from the subjects in the low dose group (no significant
decrease in plasma phosphate concentration) and the observa-
tion from other studies that the greatest reductions in plasma
2. Prevention of NH4Cl-induced hypophosphatemia by either adminis-
tering large oral doses of neutral phosphate or by pharmacologically
increasing renal tubular phosphate reabsorption (e.g., by diphospho-
nates) might be considered to yield more direct evidence for the hy-
pothesis that hypophosphatemia and/or cellular phosphate depletion
is the sole determinant of elevated serum 1,25-(OH)2D concentration
during metabolic acidosis. However, even massive increases in oral
phosphate intake (95.8 mmol/d) have been insufficient to increase
fasting plasma phosphate concentration in humans with metabolic aci-
dosis (41). Moreover, this approach would not be useful even if nor-
mophosphatemia was achievable inasmuch as phosphate loading of
this magnitude would almost certainly result in severe hyperparathy-
roidism. Diphosphonates, on the other hand, have been shown to exert
independent effects on intestinal calcium transport, vitamin D, and
bone metabolism (61). Thus, currently available diphosphonates are
of insufficient specificity to further address this question.
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Figure 3. (A) Relation between steady state plasma phosphate (P04) and plasma bicarbonate (HC03) concentrations. Steady state data from all
subjects in the high dose and low dose groups were pooled. Closed circles represent fasting, morning values (0700); open circles represent non-
fasting, evening values ( 1800). (B) Relation between steady state serum 1,25-(OH)2D and plasma phosphate (PO4) concentrations. Steady state
data from all subjects in the high and low dose groups were pooled. Closed circles represent fasting, morning values (0700); open circles represent
nonfasting, evening values (1800). (C) Relation between steady state serum 1,25-(OH)2D and plasma bicarbonate (HCO ) concentrations.
Steady state data from all subjects in the high and low dose groups were pooled. Closed circles represent fasting, morning values (0700); open
circles represent nonfasting, evening values ( 1800).
phosphate concentration occurred at lowest plasma bicarbon-
ate concentration indicate that the development of significant
hypophosphatemia depends on the severity of metabolic acido-
sis. In this context, it is interesting to note that, of the previous
reported measurements of serum 1,25-(OH)2D concentration
during experimentally induced metabolic acidosis (15-19),
the only study that found an acidosis-induced increase in
serum 1,25-(OH)2D ( 16) also demonstrated the most severe
degree of acidosis (mean plasma [HCOfl = 11 mmol/liter)
accompanied by significant NH4Cl-induced hypophosphate-
mia. In addition, none of the previous reports has analyzed the
correlation of steady state plasma phosphate and bicarbonate
concentration.
Chronic NH4C1 administration has been reported previ-
ously in humans to increase renal phosphate clearance (37),
which accounts for most of the negative phosphate balance
during prolonged acidosis (36). The present studies demon-
strating increased fractional excretion of phosphate despite
steady state hypophosphatemia are consistent with an acidosis-
induced renal phosphate leak. The cellular mechanism(s) of
decreased renal tubular phosphate reabsorption in response to
acidosis is (are) currently unknown.
Chronic dietary potassium loading has been reported re-
cently to result in chronic renal hyperphosphatemia and de-
creased 1,25- (OH )2D serum concentration (32). Wetherefore
considered the possibility that the renal potassium wasting of
mineral acidosis might be responsible for both hypophosphate-
mia and secondarily increased serum 1,25-(OH)2D concentra-
tion. However, no significant correlation was obtained for the
relation of steady state values of plasma phosphate on potas-
sium concentration (r = 0.475, n = 16). A statistically signifi-
cant inverse correlation does obtain for serum 1,25-(OH)2D
on plasma potassium concentration (r = 0.542, n = 16), but
this correlation is substantially less significant than the correla-
tion for serum 1,25-(OH)2D on plasma phosphate concentra-
tion (r = 0.71 1, n = 16; Fig. 3 B). These results suggest that
other factors in addition to potassium homeostasis determine
both plasma phosphate and serum 1,25-(OH)2D concentra-
tions in chronic mineral acidosis. The possibility of an ancillary
direct phosphate-independent effect of potassium metabolism
on 1,25-(OH)2D production in metabolic acidosis can not be
excluded by the present results. However, there are no reported
effects of potassium metabolism on 1,25- (OH)2D metabolism.
The present results in acidotic human subjects might ap-
pear to disagree with the repeated finding in rats that chronic
mineral acidosis results in significant decreases in serum 1,25-
(OH)2D concentration ( 17-19). However, in each of the pro-
tocols in rats, chronic metabolic acidosis was associated with
increased plasma ionized calcium concentration ( 17-19).
Chronic hypercalcemia is known in several species to be able to
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Figure 4. Effect of chronic metabolic acidosis on steady state diurnal
variations in plasma ionized calcium (Ca"+) and phosphate (PO4)
concentrations and serum intact parathyroid hormone (PTH) and
1,25-(OH)2D concentrations. Open circles and broken line represent
control; closed circles and solid lines represent experimental (NH4CI
feeding) periods, respectively.







PR and serum concentration of 1,25-(OH)2D (23, 45, 46).
Only when hypophosphatemia/cellular phosphate depletion is
severe has acidosis-induced hypercalcemia failed to suppress a
hypophosphatemia-induced increase in serum 1,25-(OH)2D
concentration (40). In the present studies, hypercalcemia was
not observed and, more importantly, a significant correlation
of serum 1,25-(OH)2D with plasma ionized calcium concen-
tration (r = 0. 17, linear slope = +29. 1 pg./ mLper mmol/liter)
did not obtain.
The finding of a significant decrease (high dose group) in
serum parathyroid hormone concentration in response to
chronic metabolic acidosis is in agreement with a previous re-
port in humans (35). However, other reports have found either
increased (47, 48) or unchanged ( 15, 39) values. Although it is
possible that the older parathyroid hormone assays were re-
sponsible for the failure to detect the small decreases in parathy-
roid hormone concentration detected herein, other explana-
tions also need to be considered. Since the dose of NH4C1ad-
ministered to the subjects of the present study (4.2 mmol/kg
per 24 h, high dose group) was substantially greater than that
employed previously, and since this large dose of NH4C1 re-
sulted in a greater decrement in steady state phosphate concen-
tration, it is possible that hypophosphatemia-induced hypo-
parathyroidism contributed to the observed decrease in intact
parathyroid hormone concentration in this group (49, 50).
The sustained elevation of serum 1,25-(OH)2D concentration
per se may also have contributed to suppression of parathyroid
hormone secretion and serum concentration (51 ).
The present experiments provide an opportunity to reinter-
pret previous observations on the role of parathyroid hormone
in metabolic acidosis. Onthe basis of measurements of immu-
noreactive NH2-terminal parathyroid hormone in chronic
NH4Cl-induced acidosis in humans (47, 48) and acute NH4Cl-
induced acidosis in rats (52), it was suggested that both acute
and chronic acidosis elicits a state of hyperparathyroidism that,
at least in rats (52), is critical to the full expression of the renal
acid excretory response. Our findings herein using the modem
two-site intact parathyroid hormone assay provide strong evi-
dence that elevated levels of parathyroid hormone per se are
not present over a wide range of values for depressed plasma
bicarbonate concentration. Thus, increased parathyroid hor-
mone secretion is not required for the renal adaptation to
chronic metabolic acidosis in humans.
The elevated serum 1,25-(OH)2D concentration in re-
sponse to chronic metabolic acidosis raises the interesting possi-
bility of a homeostatic role for 1,25-(OH)2D metabolism in
moderate to severe acidosis. That is, does the elevated serum
1,25-(OH)2D contribute to the normal acid excretory re-
sponse? This question will require further evaluation in view of
the observations that vitamin Ddeficiency has been reported to
cause metabolic acidosis in chicks (53) and chronic 1,25-
(OH)2D administration results in metabolic alkalosis (in part
of renal origin) in thyroparathyroidectomized dogs (54, 55).
The results of the present studies help to integrate a number
of interesting issues regarding the complex and interrelated
pathophysiology of metabolic acidosis, hypophosphatemia,
and metabolic bone disease. First, 1,25-(OH)2D is a potent
stimulus to bone resorption (56, 57). Second, mild phosphate
depletion has been shown to enhance bone resorption and to
decrease bone mineralization in rats (58). Moreover, the sever-
ity of hypophosphatemia-induced enhanced bone resorption
was greatly attenuated by experimental vitamin D deficiency.
Third, rats with chronic mineral acidosis and associated hypo-
phosphatemia exhibit increased bone resorption as well as de-
creased bone formation (59, 60). Fourth, hypophosphatemia
is often present during chronic acidosis of either renal tubular
or extrarenal etiology (59, 60) and the reversal of skeletal le-
sions by alkali treatment alone is associated with a markedly
positive phosphate balance ( 3, 5 ). Taken together with the pres-
ent findings that chronic metabolic acidosis induces acid load-
dependent hypophosphatemia and increased serum 1,25-
(OH)2D concentration, the possibilities might therefore be con-
sidered that the renal hypophosphatemia/phosphate depletion
of chronic metabolic acidosis plays a fundamental pathoge-
netic role in the development of metabolic bone disease and
high levels of serum 1,25-(OH)2D concentration may play a
deleterious role in the development of metabolic bone disease
in chronic acidosis.
In summary, chronic extrarenal metabolic acidosis in-
creases both MCRand PRof 1,25-(OH)2D in humans. At the
lower plasma bicarbonate concentrations of more severe acido-
sis, the increase in production rate overrides the increase in
MCR, resulting in a significant increase in serum 1 ,25-(OH)2D
concentration. The strong inverse correlation between serum
1,25-(OH)2D and plasma phosphate concentration suggests
that acidosis-induced hypophosphatemia and/or cellular phos-
phate depletion play a critical role in stimulating the PR of
1,25-(OH)2D.
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